Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Update on SARS research and other possibly zoonotic coronaviruses∗

Larry J. Anderson*, Suxiang Tong

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS A34, 1600 Clifton Rd, Atlanta, GA 30333, USA

A R T I C L E   I N F O

Keywords:
SARS
Coronavirus
Zoonosis
Pathogenesis
Public health

A B S T R A C T

The global outbreak of severe acute respiratory syndrome (SARS) in 2003 led to an intense and effective global response that stopped the spread of the disease by July 2003. There was also an intensive and very productive research effort to identify the etiological agent, characterise the clinical and epidemiological features of the disease, understand the pathogenesis of the disease and the molecular biology of the virus, and design antiviral drugs and vaccines to treat and prevent the disease. In parallel with the SARS research effort there have been continuous improvements in our ability to detect and characterise other novel viruses. The SARS outbreak illustrates the importance of such detection tools in the response to public health threats. Studies since the SARS outbreak suggest that many novel viruses exist in animals and some, but probably not many, will present a risk to humans.

Published by Elsevier B.V. on behalf of International Society of Chemotherapy.

On 11 February 2003 China reported to the World Health Organisation (WHO) that 305 cases of atypical pneumonia of unknown aetiology had been identified in Guangdong Province since 16 November 2002, and that five people had died. On 21 February 2003 a physician from Guangdong Province, ill with atypical pneumonia, visited Hong Kong and stayed overnight in Hotel M. The agent that caused his illness, severe acute respiratory syndrome coronavirus (SARS CoV), was transmitted to at least 10 persons, who subsequently initiated outbreaks in Hong Kong, Singapore, Viet Nam, and Canada [1]. Thus a global outbreak was initiated. The outbreak triggered a successful global response to control the spread of the disease, and a very productive research effort. One outcome of the SARS and parallel research programmes has been the development of increasingly powerful molecular tools to identify and characterise novel, including zoonotic, pathogens. The response to SARS and the associated research activities demonstrated the public health benefits of these detection tools and the challenges associated with their use.

The severity of the illness associated with SARS CoV infection, and its rapid global spread, led to the intensive response effort. Most of those severely infected with SARS CoV had lower respiratory tract illness, an infiltrate on chest radiograph and were hospitalised. A high percentage of those hospitalised required intensive care, and many died. The overall mortality rate was ∼10% but reached nearly 50% in elderly persons. To the surprise of some, SARS transmission was stopped by the end of June, just over 4 months after the initiation of global spread from Hotel M in Hong Kong.

There have subsequently been three instances of laboratory-acquired infection, one in Singapore [2], one in Taiwan [3] and one in China [4] in 2003 and 2004, and one reintroduction from animals in Guangdong Province, China in December 2003 and January 2004 [5]. None of these occurrences had sufficient secondary human-to-human transmission to generate a threat of a recurrent global outbreak. The laboratory-acquired infection in China was, however, associated with limited community transmission, which highlighted the potential risk to the community of a breach in biosafety procedures in laboratories working on SARS CoV.

The rapid control of SARS CoV during the global outbreak of 2003, and the limited spread during subsequent reintroductions, likely result both from the characteristics of the virus and the effectiveness of control efforts. Features of SARS CoV infection that facilitated its control include: (1) a very high prevalence of serious illness, making it easier to identify cases and know where transmission was occurring and (2) a low risk of transmission before the patient was seriously ill and likely to be hospitalised, diagnosed and placed in isolation.

Case identification and isolation followed by contact identification and management were responsible for limiting the spread of and ultimately stopping the outbreak. Case identification and isolation were usually straightforward if the risk of exposure was recognised, but contact identification and management were sometimes more problematic. Recognition of all potential contacts and implementation of measures to rapidly identify and isolate those that had become infected prevented further spread. Missing potential contacts, on the other hand, sometimes led to unrecognised disease and substantial transmission, as illustrated by one instance in Canada [6] and one in Taiwan [7]. In both instances the extent of

∗ Corresponding author. Tel.: +1 404 639 3596; fax: +1 404 639 1307. E-mail address: lja2@cdc.gov (L.J. Anderson).

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

doi:10.1016/j.ijantimicag.2010.06.016
nosocomial transmission was underappreciated, and contacts that were not identified and became infected spread the virus to others.

Contacts can be managed in different ways, with the appropriateness of the different strategies depending on the extent and risk of the exposure [8–10]. Less stringent strategies are appropriate for low-risk exposures and more stringent ones for high-risk exposures. Some approaches to contact management are: (1) telling contacts about their possible exposure to SARS CoV and providing guidance on what to do if they develop a SARS-like illness, (2) actively monitoring contacts for illness and placing them in isolation and (3) placing contacts in quarantine.

Also key to stopping global transmission was WHO’s timely updates on where SARS cases were occurring, the clinical and epidemiological features of infection, laboratory methods, and strategies to control spread. WHO’s ability to coordinate the intensive and collaborative global response to SARS was impressive.

The aetiological agent, SARS CoV, was identified within weeks of global spread [11–13] and this discovery was followed by an impressive sequence of research accomplishments. These included the development of diagnostic assays; the characterisation of the clinical, epidemiological and virological features of infection [14]; the identification and initial evaluation of antiviral drugs (Table 1) [15–17]; the development of animal models of SARS CoV infection [18–22]; the development and evaluation of candidate vaccines (Table 2) [23–26]; the identification of receptors for SARS CoV [27,28]; the development of a reverse genetics system [29] and more. From the discovery of the virus in March 2003, until October 2009, there have been ∼3000 articles published on the virus, the clinical and epidemiological features of infection, the social and societal impact of the outbreak and the treatment and prevention of the disease.

One of the early findings after the discovery of the SARS CoV was the near absence of SARS CoV antibodies in those who were not SARS cases [12,13,30]. This finding demonstrated that SARS CoV had not circulated to any significant extent in humans before 2003 and was introduced into humans from animals. Reports of multiple independent early cases from Guangdong Province during the first outbreak in November 2002 and February 2003, and reports of non-linked cases during the second outbreak in December 2003 and January 2004 [5,31], suggested that the animal reservoir for SARS CoV had contact with humans, directly or indirectly, in multiple locations. Initial studies in humans and animals in wild-animal markets in Guangdong Province suggested that animals in these markets might be the source of human infection (Table 3) [32]. However, subsequent studies showed that SARS infection in animals before arrival in the markets was uncommon and these animals were therefore not the original reservoir of the outbreak virus.

Two studies published in 2005 identified bats as the likely reservoir for SARS CoV [33,34]. In these studies, horseshoe bats from China were shown to have a high rate of antibodies that reacted against SARS CoV antigens or a high level of SARS CoV-like RNA in faecal specimens (Table 4). The sequences of the amplified RNA were closely related but not identical to SARS CoV, with ∼8% differences from SARS CoV in multiple genes. This level of difference was too great for the RNA to be from the parent to the outbreak virus. However, the presence of multiple SARS CoV-like viruses, the inability to detect SARS CoV-like viruses in other species of wild-living animals and the detection of a wide range of other coronaviruses in bats suggests that they are a rich source of coronavirus and the most likely animal reservoir for the SARS outbreak virus [35–37].

Analysis of the RNA sequences of outbreak isolates over time suggests that once introduced into humans the virus adapted. Sequential isolates from early but not later in the outbreak showed

---

### Table 1
Types of antiviral drugs developed for severe acute respiratory syndrome coronavirus.

| Mode of action          | Drug                                      |
|-------------------------|-------------------------------------------|
| Virus entry blockers    | Anti-S protein monoclonal antibodies      |
|                         | Peptides that bind to the heptad repeat on the S (spike) protein |
|                         | Peptides that bind to other regions of S and block oligomerisation, etc. |
| Virus replication blockers | 3C-like protease inhibitors               |
|                         | Other viral protease inhibitors, e.g. papain-like cysteine protease nsp1–16 |
|                         | Viral polymerase inhibitors               |
|                         | Nelfinavir, lopinavir/ritonavir, ribavirin, RNAI, glycyrhrizin, niclosamide |
| Immune modulators       | Type 1 interferons                        |
|                         | Lopinavir/ritonavar                       |

Adapted from Groneberg et al. [15] and Tong et al. [16,17].

### Table 2
Vaccines for severe acute respiratory syndrome.

| Vaccine type                  | Animal studies | Induction of neutralizing antibodies and/or protection | Human trials |
|------------------------------|----------------|--------------------------------------------------------|--------------|
| Inactivated virus            | Mice           | +                                                     | +            |
| Subunit or expressed protein | Mice           | +                                                     | –            |
| Viral or bacterial expression vectors (S or N protein) | Mice, ferrets, primates | +                                                     | –            |
| DNA vaccine (S, N, M protein) | Mice, primates | +                                                     | +            |
| Live attenuated virus        | Hamsters       | +                                                     | –            |

Adapted from Enjuanes et al. [23], Gillim-Ross et al. [24], Lin et al. [25] and Martin et al. [26].

### Table 3
Severe acute respiratory syndrome coronavirus (SARS CoV) in a wild-animal market, Guangdong Province, China, 2003.

| Animal                  | Positive by RT-PCR or isolation | SARS CoV antibody-positive |
|-------------------------|--------------------------------|---------------------------|
|                         | Nasal | Rectal | Serum |                     |
| Civet cat               | 6/6   | 5/6    | 3/4   |                     |
| Raccoon dog             | 0/1   | 1/1    | 1/1   |                     |
| Chinese ferret-badger   | 0/2   | 0/2    | 1/2   |                     |
| Hog-badger              | 0/3   | 0/3    | 0/1   |                     |
| Domestic cat            | 0/4   | 0/4    | 0/3   |                     |
| Chinese hamster, hare, muntjac and beaver | 0/8   | 0/8    | 0/7   |                     |

RT-PCR, reverse transcription polymerase chain reaction. Adapted from Guan et al. [32].
Table 4
Severe acute respiratory syndrome-like coronaviruses in bats and other mammals.

| Source                  | Location                          | Antibodies in sera N (tested) | PCR-positive faeces N (tested) |
|------------------------|-----------------------------------|------------------------------|--------------------------------|
| Lau et al. [33]        | Hong Kong                         | 31 (37)                      | 23 (59)                        |
| Rhinolophus sinicus bats (59) |                              |                              |                                |
| Other bats (68)        |                                   |                              |                                |
| Other mammals (60 rodents, 20 monkeys) |                          |                              |                                |
| Li et al. [34]         | Three provinces of China          | 20 (63)                      | 5 (67)                         |
| Rhinolophus pearsoni, R. pusillus, R. ferrumequinum, macrotis bats | |                              |                                |
| Other bats             |                                   | 2 (204)                      | 0 (261)                        |

Fig. 1. Phylogenetic relationships of 64 coronaviruses isolated from bats in China. The tree was generated based on 440 nucleotides of the RNA-dependent RNA polymerase region by the neighbour-joining method in the MEGA programme. Numbers above branches indicate neighbour-joining bootstrap values (percent) calculated from 1000 bootstrap replicates. Terminal nodes containing bat coronaviruses isolated in this study are collapsed and represented by a triangle with the number of viruses indicated within. The tree was rooted to Breda virus (AY427798). Scale bar: 0.05 substitution per site. Abbreviated blue text in parentheses indicates provinces from where viruses were isolated. AH, Anhui; FJ, Fujian; GD, Guangdong; GX, Guangxi; HA, Hainan; HB, Hubei; HE, Henan; JX, Jiangxi; SC, Sichuan; SD, Shandong; YN, Yunnan. Adapted from Tang et al. [49]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of the article.)
As already mentioned, the SARS outbreak led to a wide range of very productive research efforts directed toward understanding the molecular biology of the infection and the pathogenesis of the disease [43,44]. The rapid development of a SARS CoV reverse genetics system has proven very useful [29]. It has not only provided a tool with which to explore the molecular virology of SARS CoV but also a means to develop candidate live-virus vaccines and generate virus strains that could not otherwise be isolated [45–48].

One concern about developing a live SARS CoV vaccine is the ability of strains of coronavirus to recombine with each other and possibly replace attenuated parts of the genome with non-attenuated genome, resulting in a pathogenic virus. Using reverse genetics, a creative approach has been developed that should eliminate the risk of recombination between coronavirus strains [47]. In this system, transcription regulatory sequences (TRSs) upstream of each gene are generated that are distinct from known coronavirus TRSS, and any recombinant virus would have different TRSS within its genome and be non-viable.

Before and since the SARS outbreak there have been continuing improvements in our ability to detect novel pathogens. At CDC the virus was isolated, characterised as a coronavirus by electron microscopy and shown to be a coronavirus distinct from the known human coronaviruses by using three PCR assays: one for 229e, one for OC43 and one for any member of the coronavirus genus [12]. Broadly reactive PCR assays have subsequently been used to detect a wide variety of coronaviruses in bat faecal specimens [35–37]. Sequence studies of the amplified genome have shown a wide range of coronaviruses representing the previously identified group I and II viruses that they may ultimately be placed of coronaviruses representing the previously identified group I and II viruses that they may ultimately be placed.

Changes in the receptor-binding domain of the S gene proved particularly interesting [40]. The S protein from a globally spread virus was found to bind more efficiently to the human angiotensin-converting enzyme 2 (ACE2) molecule than a virus from a civet cat and a virus from the cluster of four cases in December 2003 and January 2004 in Guangdong Province, China. The investigators identified critical amino acids in the receptor-binding domain of the S protein of the globally spread virus that were associated with increased binding efficiency to the human ACE2 molecule. They also identified amino acids in the ACE2 molecule associated with S protein-binding efficiency. The importance of the receptor-binding domain for adaptation to human infection is supported by in vitro studies showing changes in this region in viruses selected for improved replication in human cells [41,42].

Various other molecular tools have been developed and applied to samples from humans, and a number of novel viruses have been detected, including novel coronaviruses [54–56], parvoviruses [57,58], polyomaviruses [59,60], astroviruses [61] and rhinoviruses [62]. These tools will continue to improve and likely identify new pathogens, some associated with disease and others of unknown significance as human pathogens. Identifying diseases that might be associated with a novel pathogen and then establishing a causal relationship between infection and the disease can be as challenging or more challenging than identifying the pathogen.

**Funding:** Funding from the US government to the Centers for Disease Control and Prevention, an agency of the US federal government, covered the studies and time included in this review article.

**Competing interests:** There are no conflicts of interest related to this article.

**Ethical approval:** All data or studies related to human subjects or animal experimentation was from previously published data by other groups. Ethical issues would have been addressed at the time of publication.

References

[1] Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med 2003;349:2431–41.

[2] Lim PL, Kurup A, Gopalakrishna G, Chan KP, Wong CW, Ng LC, et al. Laboratory-acquired severe acute respiratory syndrome. N Engl J Med 2004;350:1740–5.

[3] Orellana C. Laboratory-acquired SARS raises worries on biosafety. Lancet Infect Dis 2004;4:64.

[4] Ensorink M, Du SARS. L. China dumps CDC head, probes lab. Science 2004;305:163.

[5] Liang G, Chen Q, Xu J, Liu Y, Lim W, Peiris JS, et al. Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg Infect Dis 2004;10:1774–81.

[6] Ofer-Agostini M, Wallington T, Henry B, Low D, McDonald LC, Berger L, et al. Identification of the second wave (phase 2) of severe acute respiratory syndrome (SARS) in Toronto, Canada. What happened? Can Commun Dis Rep 2008;34:1–11.

[7] Severe acute respiratory syndrome—Taiwan, 2003. Morb Mortal Wkly Rep 2003;52:461–6.

[8] Pang X, Zhu Z, Xu F, Guo J, Gong X, Liu D, et al. Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing, 2003. JAMA 2003;290:3215–21.

[9] St John RK, Long A, de Jong D, Bodie-Collins M, Squires SG, Tam TW. Border screening for SARS. Emerg Infect Dis 2005;11:6–10.

[10] Svoboda T, Henry B, Shulman L, Kennedy E, Rea E, Ng W, et al. Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto. N Engl J Med 2004;350:2352–61.

[11] Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967–76.

[12] Kusneek TG, Erdman DD, Goldsmith CS, Zaki SR, Peret TC, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953–66.

[13] Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319–25.

[14] Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med 2004;10(12 Suppl):S88–97.

[15] Groneberg DA, Poutanen SM, Low DE, Lode H, Weitte T, Zabel P. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis 2005;5:147–55.

[16] Tong TR. Therapies for coronaviruses. Part I of II — viral entry inhibitors. Expert Opin Ther Pat 2009;19:357–67.

[17] Tong TR. Therapies for coronaviruses. Part 2. Inhibitors of intracellular life cycle. Expert Opin Ther Pat 2009;19:415–31.

[18] Roberts A, Paddock C, Vogel L, Butler E, Zaki S, Subbarao K. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol 2005;79:8331–8.

[19] Roberts A, Vogel L, Guerier J, Hayes N, Murphy B, Zaki S, et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol 2005;79:503–11.

[20] McAuliffe J, Vogel L, Roberts A, Fahle G, Fischer S, Shieh WJ, et al. Replication of SARS coronavirus administered into the respiratory tract of African green, rhesus and cynomolgus monkeys. Virology 2004;330:8–15.

[21] Martina BE, Haagmans BL, Kuiken T, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, et al. Virology: SARS virus infection of cats and ferrets. Nature 2003;425:915.

[22] Baric RS, Sims AC. Humanized mice develop coronavirus respiratory disease. Proc Natl Acad Sci U S A 2005;102:8073–4.
L.J. Anderson, S. Tong / International Journal of Antimicrobial Agents 36S (2010) S21–S25

S25

[23] Enjuanes L, Dediego ML, Alvarez E, Deming D, Sheahan T, Baric R. Vaccines to prevent severe acute respiratory syndrome coronavirus–induced disease. Virus Res 2008;133:45–62.

[24] Gillim-Roxo L, Subbarao K. Emerging respiratory viruses: challenges and vac- cine strategies. Clin Microbiol Rev 2006; 19:614–36.

[25] Lin JT, Zhang JS, Su N, Xu JG, Wang N, Chen JT, et al. Safety and immuno- genicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther 2007; 12:1107–13.

[26] Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008; 26:6338–43.

[27] Marzi A, Gramberg T, Simmons G, Moller P, Rennekamp AJ, Krumbiegel M, et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol 2004; 78:12090–5.

[28] Moore MJ, Dorfman T, Li W, Wong SK, Li Y, Kuhn JH, et al. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol 2004; 78:10628–35.

[29] Yount B, Curtis KM, Fritz EA, Hensley LE, Jahrling PB, Prentice E, et al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 2003; 100:12995–3000.

[30] Chan KH, Poon LL, Cheng VC, Guan Y, Hung IF, Kong J, et al. Detection of SARS coronavirus in patients with suspected SARS. Emerg Infect Dis 2004; 10:294–9.

[31] Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH, et al. Epidemiology and cause of the SARS epidemic in China. Science 2004; 303:1666–9.

[32] Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302:276–8.

[33] Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, et al. Severe acute respir- atory syndrome coronavirus–like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 2005; 102:14040–5.

[34] Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like and other coronaviruses in bats from Kenya. Emerg Infect Dis 2009; 15:1377–84.

[35] Pfefferle S, Oppong S, Drexler JF, Gloza-Rausch F, Ippen A, Seebens A, et al. Distant relatives of severe acute respiratory syndrome coronavirus and the S protein of severe acute respiratory syndrome coronavirus. J Virol 2004; 78:12090–5.

[36] Tong S, Conrardy C, Ruome S, Kuzmin IV, Guo X, Tao Y, et al. Detection of novel SARS–like and other coronaviruses in bats from Kenya. Emerg Infect Dis 2009; 15:1377–84.

[37] Yount B, Roberts RS, Lindsell SM, Baric RS. Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineer- ing a recombination-resistant genome. Proc Natl Acad Sci U S A 2006; 103:12546–51.

[38] Yount B, Roberts RS, Sims AC, Deming D, Friedman MB, Sparks J, et al. Severe acute respiratory syndrome coronavirus group–specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol 2005; 79:14909–22.

[39] Tang XC, Zhang JX, Zhang SY, Wang P, Fan XH, Li LF, et al. Prevalence and genetic diversity of coronaviruses in bats from China. J Virol 2006; 80:7481–90.

[40] Drexler JF, Cormon VM, Gloza-Rausch F, Seebens A, Ippen A, Ippen E, et al. Novel Henipavirus RNA in African bats. PLoS One 2009; 4:e6367.

[41] Misra V, Dumonceaux T, Dubois J, Willis C, Nadin-Davis S, Severini A, et al. Detection of polyoma and corona viruses in bats of Canada. J Gen Virol 2005; 86:2015–22.

[42] Zhuc HU, Chu DK, Liu W, Dong BQ, Zhang JX, Zhuc JX, et al. Detection of diverse astroviruses from bats in China. J Gen Virol 2009; 90:883–7.

[43] Maeda K, Hondo E, Terakawa J, Kiso Y, Nakai Chi, Nendo D, et al. Detection of novel adenovirus from bat (Peropos dussumylus yoyoyamae). Emerg Infect Dis 2008; 14:347–9.

[44] Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH, et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci U S A 2004; 101:6212–6.

[45] van der Hoek L, Pyrc K, Jellink MF, Vermeulen-Oost W, Berkhouh R, Walkers KC, et al. Identification of a new human coronavirus. Nat Med 2004; 10:688–73.

[46] Woon PC, Lau SK, Chu CM, Chan KH, Tsui HW, Huang Y, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005; 79:884–95.

[47] Allander T, Tammi MT, Eriksson M, Bjerkan A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A 2005; 102:12891–6.

[48] Jones MS, Kapoor A, Lukashov MV, Simmonds P, Hecht F, Delwart E. New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005; 79:8230–6.

[49] Allander T, Andreasen K, Gupta S, Bjerkan A, Bogdanovic G, Persson MA, et al. Identification of a third human polyomavirus. J Virol 2007; 81:4130–6.

[50] Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, Wu G, et al. Identifi- cation of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog 2007; 3:e64.

[51] Finkbeiner SR, Li Y, Ruome S, Conrardy C, Gregoricos N, Toney D, et al. Identifi- cation of a novel astrovirus (Astrovirus VA1) associated with an outbreak of acute gastroenteritis. J Virol 2009; 83:10836–9.

[52] Lamson D, Renwick N, Kapoor V, Liu Z, Palacios G, Ju J, et al. MassTag polymerase-chain-reaction detection of respiratory pathogens, including a new rhinovirus genotype, that caused influenza-like illness in New York State during 2004–5. J Infect Dis 2006; 194:1398–402.